NEW YORK--(BUSINESS WIRE)--
Phreesia, Inc. (NYSE: PHR) (“Phreesia”) announced financial results today for the fiscal fourth quarter and year ended January 31, 2020.
Fiscal Fourth Quarter 2020 Highlights
-
Revenue was $32.8 million in the quarter as compared to $26.5 million in the same period in the prior year, an increase of 24%.
-
Average number of provider clients was 1,603 in the quarter as compared to 1,543 in the same period in the prior year, an increase of 4%.
-
Average revenue per provider client was $16,708 in the quarter compared to $14,219 in the same period in the prior year, an increase of 18%.
-
Adjusted EBITDA was $1.3 million in the quarter compared to $0.4 million in the same period in the prior year.
-
Cash on the balance sheet as of January 31, 2020 was $90.3 million, down $1.1 million from October 31, 2019.
Fiscal Year End January 31, 2020 Highlights
-
Revenue was $124.8 million in fiscal 2020 as compared to $99.9 million in fiscal 2019, an increase of 25%.
-
Average number of provider clients was 1,571 in fiscal 2020 as compared to 1,490 in fiscal 2019, an increase of 5%.
-
Average revenue per provider client was $65,486 in fiscal 2020 as compared to $54,231 in fiscal 2019, an increase of 21%.
-
Adjusted EBITDA was $4.8 million in fiscal 2020 as compared to $3.5 million in fiscal 2019.
-
Cash on the balance sheet as of January 31, 2020 was $90.3 million, up $88.8 million from January 31, 2019.
Conference Call Information
The Company will hold a conference call on Thursday, April 23, 2020, at 8:30 a.m. Eastern Time to review the Company’s fiscal fourth quarter and fiscal year 2020 financial results. To participate in the Company’s live conference call and webcast, please dial (866) 211-4557 (or (647) 689-6750 for international participants) using conference code number 2346258 or visit the “Events & Presentations” section of ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
Recent Events
The Company filed a Current Report on Form 8-K on April 6, 2020 (the “8-K”) to provide an update related to the outbreak of a novel strain of Coronavirus (“COVID-19”) and its impact on the Company’s business. As set forth in the 8-K, COVID-19 has and could continue to materially and adversely impact Phreesia’s business and results of operations. However, the rapid development and fluidity of this situation precludes any prediction as to the ultimate adverse impact of COVID-19. During the interim period since the filing of the 8-K, there has been no change to the information disclosed therein.
|
Phreesia, Inc.
Balance sheets
(Unaudited)
in thousands, except for shares and per share data
|
|
|
|
|
|
|
January 31,
2020
|
|
January 31,
2019
|
|
Assets
|
|
|
|
|
Current:
|
|
|
|
|
Cash and cash equivalents
|
$
|
90,315
|
|
|
$
|
1,543
|
|
|
Settlement assets
|
12,368
|
|
|
10,217
|
|
|
Accounts receivable, net of allowance for doubtful accounts of $943 and $517
|
21,978
|
|
|
16,073
|
|
|
Deferred contract acquisition costs
|
1,720
|
|
|
1,673
|
|
|
Prepaid expenses
|
5,157
|
|
|
3,811
|
|
|
Total current assets
|
$
|
131,538
|
|
|
$
|
33,317
|
|
|
Property and equipment, net of accumulated depreciation and amortization of $35,551 and $27,862
|
14,487
|
|
|
14,211
|
|
|
Capitalized internal-use software, net of accumulated amortization of $19,554 and $14,621
|
8,735
|
|
|
7,816
|
|
|
Deferred contract acquisition costs
|
1,594
|
|
|
1,521
|
|
|
Intangible assets, net of accumulated amortization of $271 and $33
|
1,199
|
|
|
1,437
|
|
|
Long-term deferred tax assets
|
775
|
|
|
—
|
|
|
Goodwill
|
250
|
|
|
250
|
|
|
Other assets
|
180
|
|
|
710
|
|
|
Total assets
|
$
|
158,758
|
|
|
$
|
59,262
|
|
|
Liabilities, Redeemable Preferred Stock and Stockholders’ Equity (Deficit)
|
|
|
|
|
Current:
|
|
|
|
|
Settlement obligations
|
$
|
12,368
|
|
|
$
|
10,217
|
|
|
Current portion of long-term debt
|
—
|
|
|
97
|
|
|
Current portion of capital leases
|
2,324
|
|
|
1,869
|
|
|
Accounts payable
|
6,017
|
|
|
3,750
|
|
|
Accrued expenses
|
9,243
|
|
|
5,507
|
|
|
Deferred revenue
|
5,401
|
|
|
6,488
|
|
|
Total current liabilities
|
$
|
35,353
|
|
|
$
|
27,929
|
|
|
Long-term debt, net of current portion
|
19,444
|
|
|
27,918
|
|
|
Capital leases, net of current portion
|
2,096
|
|
|
2,401
|
|
|
Warrant liability
|
—
|
|
|
5,498
|
|
|
Total liabilities
|
$
|
56,893
|
|
|
$
|
63,746
|
|
|
Redeemable preferred stock:
|
|
|
|
|
Senior A redeemable preferred stock, $0.01 par value—14,500,000 shares authorized as of January 31, 2019; 13,674,365 issued and outstanding as of January 31, 2019;
|
—
|
|
|
79,311
|
|
|
Series B redeemable convertible preferred stock, $0.01 par value—10,820,169 shares authorized as of January 31, 2019; 9,197,142 shares issued and outstanding as of January 31, 2019;
|
—
|
|
|
51,872
|
|
|
Junior convertible preferred stock, $0.01 par value—34,000,000 shares authorized as of January 31, 2019; 32,746,041 shares issued and outstanding as of January 31, 2019;
|
—
|
|
|
32,746
|
|
|
Redeemable preferred stock, $0.01 par value— 44,000,000 shares authorized as of January 31, 2019; 42,560,530 shares issued and outstanding as of January 31, 2019;
|
—
|
|
|
42,561
|
|
|
Total redeemable preferred stock
|
—
|
|
|
206,490
|
|
|
Stockholders’ Equity (Deficit):
|
|
|
|
|
Common stock, $0.01 par value—500,000,000 and 80,000,000 shares authorized as of January 31, 2020 and January 31, 2019, respectively; 36,610,763 and 1,994,721 shares issued and outstanding as of January 31, 2020 and January 31, 2019, respectively
|
366
|
|
|
20
|
|
|
Additional paid-in capital
|
386,383
|
|
|
—
|
|
|
Accumulated deficit
|
(284,485
|
)
|
|
(210,994
|
)
|
|
Treasury stock
|
$
|
(399
|
)
|
|
—
|
|
|
Total stockholders’ equity (deficit)
|
$
|
101,865
|
|
|
$
|
(210,974
|
)
|
|
Total Liabilities, Redeemable Preferred Stock and Stockholders’ Equity (Deficit)
|
$
|
158,758
|
|
|
$
|
59,262
|
|
|
Phreesia, Inc.
Statements of Operation
(Unaudited)
in thousands, except for shares and per share data
|
|
|
|
|
|
|
|
Three months ended January 31,
|
|
Fiscal year ended January 31,
|
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
|
Revenue:
|
|
|
|
|
|
|
|
|
Subscription and related services
|
$
|
15,064
|
|
|
$
|
12,537
|
|
|
$
|
56,357
|
|
|
$
|
43,928
|
|
|
Payment processing fees
|
11,719
|
|
|
9,403
|
|
|
46,500
|
|
|
36,881
|
|
|
Life sciences
|
6,032
|
|
|
4,543
|
|
|
21,927
|
|
|
19,080
|
|
|
Total revenues
|
32,815
|
|
|
26,483
|
|
|
124,784
|
|
|
99,889
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
Cost of revenue (excluding depreciation and amortization)
|
4,237
|
|
|
4,473
|
|
|
16,831
|
|
|
15,105
|
|
|
Payment processing expense
|
6,936
|
|
|
5,582
|
|
|
27,889
|
|
|
21,892
|
|
|
Sales and marketing
|
8,187
|
|
|
6,396
|
|
|
32,357
|
|
|
26,367
|
|
|
Research and development
|
4,860
|
|
|
4,205
|
|
|
18,623
|
|
|
14,349
|
|
|
General and administrative
|
9,609
|
|
|
5,958
|
|
|
30,458
|
|
|
20,076
|
|
|
Depreciation
|
2,310
|
|
|
2,037
|
|
|
8,753
|
|
|
7,552
|
|
|
Amortization
|
1,348
|
|
|
1,130
|
|
|
5,171
|
|
|
4,042
|
|
|
Total expenses
|
37,487
|
|
|
29,782
|
|
|
140,082
|
|
|
109,382
|
|
|
Operating loss
|
(4,672
|
)
|
|
(3,299
|
)
|
|
(15,298
|
)
|
|
(9,494
|
)
|
|
Other income (expense)
|
(283)
|
|
|
(173
|
)
|
|
(1,023
|
)
|
|
(7
|
)
|
|
Change in fair value of warrant liability
|
—
|
|
|
(562
|
)
|
|
(3,307
|
)
|
|
(2,058
|
)
|
|
Interest income (expense)
|
(676
|
)
|
|
(1,045
|
)
|
|
(2,445
|
)
|
|
(3,504
|
)
|
|
Total other income (expense)
|
(959
|
)
|
|
(1,780
|
)
|
|
(6,775
|
)
|
|
(5,568
|
)
|
|
Loss before benefit from (provision for) income taxes
|
(5,631
|
)
|
|
(5,080
|
)
|
|
(22,073
|
)
|
|
(15,062
|
)
|
|
Benefit from (provision for) income taxes
|
1,963
|
|
|
—
|
|
|
1,780
|
|
|
—
|
|
|
Net loss
|
(3,668
|
)
|
|
(5,080
|
)
|
|
(20,293
|
)
|
|
(15,062
|
)
|
|
Preferred stock dividend paid
|
—
|
|
|
—
|
|
|
(14,955
|
)
|
|
—
|
|
|
Accretion of redeemable preferred stock
|
—
|
|
|
—
|
|
|
(56,175
|
)
|
|
(30,199
|
)
|
|
Net loss attributable to common stockholders, basic and diluted
|
$
|
(3,668
|
)
|
|
$
|
(5,080
|
)
|
|
$
|
(91,423
|
)
|
|
$
|
(45,261
|
)
|
|
Net loss per share attributable to common stockholders, basic and diluted
|
$
|
(0.10
|
)
|
|
$
|
(2.58
|
)
|
|
$
|
(4.50
|
)
|
|
$
|
(24.53
|
)
|
|
Weighted-average common shares outstanding, basic and diluted
|
36,010,388
|
|
|
1,971,031
|
|
|
20,301,189
|
|
|
1,844,929
|
|
|
Phreesia, Inc.
Statements of Cash Flows
(Unaudited)
in thousands, except for shares and per share data
|
|
|
|
|
|
For the fiscal years ended January 31,
|
|
|
2020
|
|
2019
|
|
2018
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
Net loss
|
$
|
(20,293
|
)
|
|
$
|
(15,062
|
)
|
|
(18,192
|
)
|
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
|
Depreciation and amortization
|
13,924
|
|
|
11,594
|
|
|
9,640
|
|
|
Stock-based compensation expense
|
6,177
|
|
|
1,447
|
|
|
805
|
|
|
Change in fair value of warrants liability
|
3,307
|
|
|
2,058
|
|
|
598
|
|
|
Amortization of debt discount
|
445
|
|
|
798
|
|
|
904
|
|
|
Loss on extinguishment of debt
|
1,073
|
|
|
—
|
|
|
—
|
|
|
Cost of Phreesia hardware purchased by customers
|
741
|
|
|
585
|
|
|
—
|
|
|
Deferred contract acquisition costs amortization
|
1,977
|
|
|
1,640
|
|
|
1,389
|
|
|
Deferred tax asset
|
(775
|
)
|
|
—
|
|
|
—
|
|
|
Changes in operating assets and liabilities
|
|
|
|
|
|
|
Accounts receivable
|
(5,905
|
)
|
|
(3,765
|
)
|
|
(3,382
|
)
|
|
Prepaid expenses and other assets
|
(312
|
)
|
|
(576
|
)
|
|
(319
|
)
|
|
Deferred contract acquisition costs
|
(2,097
|
)
|
|
(2,500
|
)
|
|
(1,773
|
)
|
|
Accounts payable
|
(30
|
)
|
|
2,367
|
|
|
(2,057
|
)
|
|
Accrued expenses and other
|
3,681
|
|
|
(2,317
|
)
|
|
1,968
|
|
|
Deferred revenue
|
(1,087
|
)
|
|
1,601
|
|
|
(723
|
)
|
|
Net cash provided by (used in) operating activities
|
$
|
826
|
|
|
$
|
(2,130
|
)
|
|
$
|
(11,142
|
)
|
|
Cash flows used in investing activities:
|
|
|
|
|
|
|
Acquisition
|
—
|
|
|
(1,190
|
)
|
|
—
|
|
|
Capitalized internal-use software
|
(5,305
|
)
|
|
(5,109
|
)
|
|
(5,375
|
)
|
|
Purchase of property and equipment
|
(7,015
|
)
|
|
(4,724
|
)
|
|
(6,590
|
)
|
|
Net cash used in investing activities
|
$
|
(12,320
|
)
|
|
$
|
(11,023
|
)
|
|
$
|
(11,965
|
)
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
Proceeds from IPO
|
$
|
130,781
|
|
|
$
|
—
|
|
|
—
|
|
|
Proceeds from revolving line of credit
|
9,876
|
|
|
14,800
|
|
|
12,400
|
|
|
Payments of revolving line of credit
|
(17,676
|
)
|
|
(7,000
|
)
|
|
(20,400
|
)
|
|
Proceeds from term loan
|
20,000
|
|
|
—
|
|
|
—
|
|
|
Proceeds from loan payable
|
—
|
|
|
—
|
|
|
10,000
|
|
|
Repayment of term loan
|
(1,042
|
)
|
|
(1,167
|
)
|
|
(1,167
|
)
|
|
Repayment of loan payable
|
(20,000
|
)
|
|
—
|
|
|
—
|
|
|
Payment of preferred stock dividends
|
(14,955
|
)
|
|
—
|
|
|
—
|
|
|
Payment on capital leases
|
(1,898
|
)
|
|
(2,470
|
)
|
|
(1,929
|
)
|
|
Debt extinguishment costs
|
(300
|
)
|
|
—
|
|
|
—
|
|
|
Debt issuance costs
|
(112
|
)
|
|
(136
|
)
|
|
(224
|
)
|
|
Proceeds from issuance of preferred stock, net
|
—
|
|
|
—
|
|
|
32,459
|
|
|
Proceeds from issuance of common stock upon exercise of stock options
|
1,809
|
|
|
361
|
|
|
147
|
|
|
Payment of offering costs
|
(6,217
|
)
|
|
(195
|
)
|
|
—
|
|
|
Net cash provided by financing activities
|
$
|
100,266
|
|
|
$
|
4,193
|
|
|
$
|
31,286
|
|
|
Net increase in cash and cash equivalents
|
88,772
|
|
|
(8,960
|
)
|
|
8,179
|
|
|
Cash and cash equivalents – beginning of period
|
1,543
|
|
|
10,503
|
|
|
2,323
|
|
|
Cash and cash equivalents – end of period
|
$
|
90,315
|
|
|
$
|
1,543
|
|
|
$
|
10,503
|
|
|
Disclosures of additional investing and financing activities:
|
|
|
|
|
|
|
Supplemental information:
|
|
|
|
|
|
|
Property and equipment acquisitions through capital leases
|
$
|
2,047
|
|
|
$
|
4,425
|
|
|
$
|
781
|
|
|
Deferred debt issuance costs included in accrued expenses
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
100
|
|
|
Deferred issuance costs included in accounts payable and accrued expenses
|
$
|
—
|
|
|
$
|
344
|
|
|
$
|
—
|
|
|
Purchase of property and equipment and capitalized software included in accounts payable
|
$
|
1,253
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Shares issued in connection with acquisition
|
$
|
—
|
|
|
$
|
162
|
|
|
$
|
—
|
|
|
Issuance of warrants related to debt
|
$
|
833
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Net exercise of preferred stock warrant
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
28
|
|
|
Cash payments for:
|
|
|
|
|
|
|
Interest
|
$
|
2,310
|
|
|
$
|
2,799
|
|
|
$
|
2,799
|
|
Non-GAAP financial measures
Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. We define Adjusted EBITDA as net income or loss, before net interest expense (income), provision for income taxes, depreciation and amortization, and before non-cash based compensation expense, non-cash change in fair value of warrant liability and net other income (expense).
We have provided below a reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP financial measure. We have presented Adjusted EBITDA in this release and our Annual Report on Form 10-K because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget, and to develop short and long-term operational plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors.
Our use of Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our financial results as reported under GAAP. Some of these limitations are as follows:
-
Although depreciation and amortization expense are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements;
-
Adjusted EBITDA does not reflect: (1) changes in, or cash requirements for, our working capital needs; (2) the potentially dilutive impact of non-cash stock-based compensation; or (3) tax payments that may represent a reduction in cash available to us; (4) other interest (expense); and
-
Other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled measures differently, which reduces its usefulness as a comparative measure.
Because of these and other limitations, you should consider Adjusted EBITDA along with other GAAP-based financial performance measures, including various cash flow metrics, net loss, and our GAAP financial results. The following table presents a reconciliation of Adjusted EBITDA to net loss for each of the periods indicated:
|
Phreesia, Inc.
Adjusted EBITDA
|
|
|
|
|
|
|
|
|
Three months ended
January 31,
|
|
Fiscal year ended
January 31,
|
|
(in thousands, unaudited)
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
|
Net loss
|
|
$
|
(3,668
|
)
|
|
$
|
(5,080
|
)
|
|
$
|
(20,293
|
)
|
|
$
|
(15,062
|
)
|
|
Interest (income) expense
|
|
676
|
|
|
1,045
|
|
|
2,445
|
|
|
3,504
|
|
|
Depreciation and amortization
|
|
3,657
|
|
|
3,167
|
|
|
13,924
|
|
|
11,594
|
|
|
Stock-based compensation expense
|
|
2,345
|
|
|
497
|
|
|
6,177
|
|
|
1,447
|
|
|
Change in fair value warrant liability
|
|
—
|
|
|
562
|
|
|
3,307
|
|
|
2,058
|
|
|
(Benefit from) provision for income taxes
|
|
(1,963
|
)
|
|
—
|
|
|
(1,780
|
)
|
|
—
|
|
|
Other (income) expense
|
|
283
|
|
|
173
|
|
|
1,023
|
|
|
7
|
|
|
Adjusted EBITDA
|
|
$
|
1,330
|
|
|
$
|
364
|
|
|
$
|
4,803
|
|
|
$
|
3,548
|
|
|
Phreesia, Inc.
Reconciliation of GAAP and Adjusted Operating Expenses (Unaudited)
|
|
|
|
|
|
|
|
|
Three months ended
January 31,
|
|
Fiscal year ended
January 31,
|
|
(in thousands)
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
|
GAAP operating expenses
|
|
|
|
|
|
|
|
|
|
General and administrative
|
|
9,609
|
|
|
5,958
|
|
|
$
|
30,458
|
|
|
$
|
20,076
|
|
|
Sales and marketing
|
|
8,187
|
|
|
6,396
|
|
|
32,357
|
|
|
26,367
|
|
|
Research and development
|
|
4,860
|
|
|
4,205
|
|
|
18,623
|
|
|
14,349
|
|
|
Cost of revenue
|
|
4,237
|
|
|
4,473
|
|
|
16,831
|
|
|
15,105
|
|
|
|
|
$
|
26,893
|
|
|
$
|
21,032
|
|
|
$
|
98,269
|
|
|
$
|
75,897
|
|
|
Stock compensation included in GAAP operating expenses
|
|
|
|
|
|
|
|
|
|
General and administrative
|
|
1,548
|
|
|
361
|
|
|
3,901
|
|
|
902
|
|
|
Sales and marketing
|
|
507
|
|
|
75
|
|
|
1,370
|
|
|
298
|
|
|
Research and development
|
|
311
|
|
|
61
|
|
|
796
|
|
|
247
|
|
|
Cost of revenue
|
|
(21
|
)
|
|
—
|
|
|
110
|
|
|
—
|
|
|
|
|
$
|
2,345
|
|
|
$
|
497
|
|
|
$
|
6,177
|
|
|
$
|
1,447
|
|
|
Adjusted operating expenses
|
|
|
|
|
|
|
|
|
|
General and administrative
|
|
$
|
8,061
|
|
|
$
|
5,597
|
|
|
$
|
26,557
|
|
|
$
|
19,174
|
|
|
Sales and marketing
|
|
7,680
|
|
|
6,321
|
|
|
30,987
|
|
|
26,069
|
|
|
Research and development
|
|
4,549
|
|
|
4,144
|
|
|
17,827
|
|
|
14,102
|
|
|
Cost of revenue
|
|
4,258
|
|
|
4,473
|
|
|
16,721
|
|
|
15,105
|
|
|
|
|
$
|
24,548
|
|
|
$
|
20,535
|
|
|
$
|
92,092
|
|
|
$
|
74,450
|
|
|
Phreesia, Inc.
Key Metrics
|
|
|
|
|
|
|
|
|
Three months ended
January 31,
|
|
Fiscal year ended
January 31,
|
|
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
|
Key Metrics:
|
|
|
|
|
|
|
|
|
|
Provider clients (average over period)
|
|
1,603
|
|
|
1,543
|
|
|
1,571
|
|
|
1,490
|
|
|
Average revenue per provider client
|
|
$
|
16,708
|
|
|
$
|
14,219
|
|
|
$
|
65,486
|
|
|
$
|
54,231
|
|
|
Patient payment volume (in millions)
|
|
$
|
477
|
|
|
$
|
369
|
|
|
$
|
1,865
|
|
|
$
|
1,446
|
|
-
Provider clients. We define provider clients as the average number of healthcare provider organizations that generate revenue each month during the applicable period. In one specific case wherein we act as a subcontractor providing white-label services to our partner’s clients, we treat this contractual relationship as a single provider client. We believe growth in the number of provider clients is a key indicator of the performance of our business and depends, in part, on our ability to successfully develop and market our Platform to healthcare provider organizations that are not yet clients. While growth in the number of provider clients is an important indicator of expected revenue growth, it also informs our management of the areas of our business that will require further investment to support expected future provider client growth. For example, as the number of provider clients increases, we may need to add to our customer support team and invest to maintain effectiveness and performance of our Platform and software for our provider clients and their patients.
-
Average revenue per provider client. We define average revenue per provider client as the total subscription and related services and payment processing revenue generated from provider clients in a given period divided by the average number of provider clients that generate revenue each month during that same period. We are focused on continually delivering value to our provider clients and believe that our ability to increase average revenue per provider client is an indicator of the long-term value of our existing provider client relationships.
-
Patient payment volume. We measure patient payment volume as the total dollar volume of transactions between our provider clients and their patients utilizing our payment platform, including via credit and debit cards, cash and check. Patient payment volume is a major driver of our payment processing revenue, and we believe that patient payment volume is an indicator of both the underlying health of our provider clients’ businesses and the continuing shift of healthcare costs to patients. Credit and debit patient payment volume processed through our payment facilitator model represented 82% and 83% of our patient payment volume in fiscal 2020 and 2019, respectively. The remainder of our patient payment volume is composed of credit and debit transactions for which Phreesia acts as a gateway to another payment processor, and cash and check transactions. Credit and debit patient payment volume processed through our payment facilitator model represented 82% and 83% in the three months ended January 31, 2020 and 2019, respectively.
Available Information
Phreesia intends to use its Company website (including its Investor Relations website) as well as its Facebook, Twitter and LinkedIn accounts as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Forward Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “going to,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern Phreesia’s plans, intentions, expectations, strategies and prospects. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, statements about our future financial performance, including our revenue, costs of revenue and operating expenses and our business outlook for fiscal 2020; our anticipated growth; our predictions about our industry; the impact of the COVID-19 pandemic on our business and our ability to attract, retain and cross-sell to healthcare provider clients. The forward-looking statements contained in this release are also subject to other risks and uncertainties, including those more fully described in Phreesia’s filings with the Securities and Exchange Commission (“SEC”), including in our Annual Report on Form 10-K that will be filed with the SEC following this earnings release. The forward-looking statements in this release are based on information available to Phreesia as of the date hereof, and Phreesia disclaims any obligation to update any forward-looking statements, except as required by law.
This press release includes certain non-GAAP financial measures as defined by SEC rules. We have provided a reconciliation of those measures to the most directly comparable GAAP measures.
ABOUT PHREESIA
Phreesia gives healthcare organizations a suite of robust applications to manage the patient intake process. Our innovative SaaS platform engages patients in their care and provides a modern, consistent experience, while enabling healthcare organizations to optimize their staffing, boost profitability and enhance clinical care.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20200422005964/en/
Investors:
Balaji Gandhi
Phreesia, Inc.
[email protected]
(929) 506-4950
Media:
Maureen McKinney
Phreesia Inc.
[email protected]
773-330-8908
Source: Phreesia, Inc.